GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers

Medicine, Rheumatology and Immunology, Basic Medical Sciences, Oncology, Life Sciences, Biochemistry, Immunology,
GRIN2A mutation   cancer immunotherapy   immune checkpoint inhibitors   tumor mutational burden   tumor-infiltrating immune cells  

GRIN2A Mutations as a Novel Indicator for Stratifying Beneficiaries of Immune Checkpoint Inhibitors in Various Cancers Background Immune checkpoint inhibitors (ICIs) therapy, which modulates the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death (ligand) 1 (PD-(L)1) pathways, has made revolutionary progress in treating v...